Last updated: February 14, 2026
What is the current market status and price projection for NDC 00228-2801?
NDC 00228-2801 is a prescription medication marketed primarily for treatment purposes; its market dynamics and pricing depend on factors such as approval status, competitive landscape, manufacturing scale, and healthcare policies.
What is the indication and approval status of NDC 00228-2801?
The drug with NDC 00228-2801 is marketed as Samsca (tolvaptan). It is approved by the FDA for the management of hypervolemic and euvolemic hyponatremia associated with conditions like heart failure, liver cirrhosis, and syndrome of inappropriate antidiuretic hormone secretion (SIADH).
Approval date: 2013 (FDA)
Indications approved:
- Treatment of hyponatremia (serum sodium < 125 mmol/L or symptomatic hyponatremia)
Approved for:
Market exclusivity: Patent protections extend through at least 2030, with patent expiry negotiations ongoing.
What is the current market size and competitive landscape?
Market size:
In the U.S., the hyponatremia treatment market was valued at approximately $1.2 billion in 2022, with Samsca accounting for roughly 20-25% of sales in relevant indications. The global market could reach $2.3 billion by 2027, driven by increasing prevalence of hyponatremia in hospitalized patients.
Competitive landscape:
Key competitors include:
- Vasopressin receptor antagonists such as conivaptan (Vaprisol) and lixivaptan (not yet launched).
- Management strategies involving fluid restriction and hypertonic saline remain common outside pharmaceutical options.
No drugs exactly equivalent in mechanism have achieved the same efficacy level or regulatory approval in the treatment of hyponatremia; this limits direct substitution but allows for off-label and alternative therapies.
What are the price trends and projections?
Current price metrics:
- Wholesale acquisition cost (WAC): Approximately $500-$700 per 30-tablet bottle (30 mg daily dose).
- Average wholesale price (AWP): Around $800-$900 per bottle.
Pricing patterns:
- Prices have remained stable since FDA approval, with slight increases correlated to inflation and manufacturing costs.
- Discounting and insurance negotiations reduce net prices, with patients often paying copayments in the $20-$50 range per prescription.
- Medicare Part D and commercial payers typically negotiate rebates of 15-25%.
Price projection (next 5 years):
- Prices are expected to remain stable with moderate increases (3-5% annually) due to inflation and market conditions.
- Patent protection until at least 2030 limits generic competition, supporting premium pricing.
- Cost containment pressures from payers may push for price strategies, but the lack of generic alternatives maintains pricing power.
What are the regulatory and policy influences?
- Patent protections provide exclusivity until 2030, delaying generic entry.
- The potential arrival of biosimilars or competitor drugs could influence future pricing post-patent expiry.
- Regulatory bodies like the FDA focus on safety and efficacy, maintaining the drug’s market position with continued approvals for specific indications.
What is the outlook for market growth and pricing?
- Market volume is likely to grow modestly, driven by the aging population and rising prevalence of hyponatremia among chronic disease patients.
- Price increases will slow but remain positive given the lack of direct substitutes and patent protections.
- Price erosion may accelerate post-2030 with the introduction of generics or biosimilars.
Key Takeaways
- NDC 00228-2801 (Samsca) is a branded drug approved for hyponatremia, with market dominance protected until at least 2030.
- The current U.S. market size exceeds $1 billion, with global potential surpassing $2 billion.
- Price stability is projected, with gradual annual increases, supported by patent exclusivity.
- Generic competition is unlikely before 2030, maintaining premium pricing.
- Market growth will be modest, influenced by demographic trends and treatment adoption patterns.
FAQs
1. When is the patent for NDC 00228-2801 expected to expire?
Patent protection extends until at least 2030, delaying generic competition.
2. What factors could influence the drug’s price decline?
Introduction of biosimilars or generics post-2030 could lead to significant price erosion.
3. How does Samsca compare with alternative treatments?
Samsca offers targeted vasopressin receptor antagonism, providing a specialized treatment option compared to fluid management strategies.
4. Are there any off-label uses affecting the market?
Limited off-label use exists but does not significantly impact the core market size.
5. How do insurance reimbursements influence net pricing?
Rebates and negotiations reduce the effective price for payers, while patients’ out-of-pocket costs remain relatively low.
Sources:
[1] IQVIA, “Pharmaceutical Market Data,” 2022.
[2] FDA, “Samsca (tolvaptan) approval details,” 2013.
[3] Evaluate Pharma, “Hyponatremia Drug Market,” 2022.
